Harmony Biosciences Holdings (HRMY) Operating Expenses (2019 - 2026)
Harmony Biosciences Holdings (HRMY) posted Operating Expenses of $133.6 million for Q1 2026, down 2.26% sequentially from $136.7 million in Q4 2025, and up 38.44% YoY from $96.5 million in Q1 2025.
Harmony Biosciences Holdings (HRMY) Operating Expenses (2019 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Operating Expenses for 8 years, with the latest figure at $133.6 million in Q1 2026.
- Quarterly Operating Expenses rose 38.44% year-over-year to $133.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $498.7 million (up 28.38% YoY) and the FY2025 annual result came in at $461.6 million, up 25.76% from the prior year.
- Operating Expenses declined to $133.6 million in Q1 2026 per HRMY's latest filing, from $136.7 million in the prior quarter.
- Over five years, Operating Expenses peaked at $136.7 million in Q4 2025 and troughed at $43.0 million in Q1 2022.
- A 5-year average of $86.2 million and a median of $82.3 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses dropped 22.93% in 2023, then soared 91.5% in 2024.
- Over 5 years, Operating Expenses stood at $53.8 million in 2022, then soared by 58.08% to $85.1 million in 2023, then climbed by 7.13% to $91.1 million in 2024, then surged by 49.98% to $136.7 million in 2025, then fell by 2.26% to $133.6 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $133.6 million, $136.7 million, and $114.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 108.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.77 Mn |
| Mar 31, 2026 | 133.58 Mn |
| Dec 31, 2025 | 136.67 Mn |
| Sep 30, 2025 | 114.32 Mn |
| Jun 30, 2025 | 114.16 Mn |
| Mar 31, 2025 | 96.49 Mn |
| Dec 31, 2024 | 91.13 Mn |
| Sep 30, 2024 | 81.55 Mn |
| Jun 30, 2024 | 119.31 Mn |
| Mar 31, 2024 | 75.10 Mn |
| Dec 31, 2023 | 85.06 Mn |
| Sep 30, 2023 | 63.46 Mn |
| Jun 30, 2023 | 62.31 Mn |
| Mar 31, 2023 | 57.92 Mn |
| Dec 31, 2022 | 53.81 Mn |
| Sep 30, 2022 | 82.35 Mn |
| Jun 30, 2022 | 54.99 Mn |
| Mar 31, 2022 | 43.04 Mn |
| Dec 31, 2021 | 44.77 Mn |
| Sep 30, 2021 | 45.08 Mn |